Valbenazine for TD

https://www.ncbi.nlm.nih.gov/m/pubmed/30695293

CONCLUSIONS: Consistent with primary published results for KINECT 3, these supplemental analyses indicate that participants treated with valbenazine (40 or 80 mg/d) had statistically significant and clinically relevant improvements in TD severity both overall and in specific body regions.